

# Karyopharm to Report Fourth Quarter and Year End 2017 Financial Results on March 15, 2018

## Conference Call Scheduled for Thursday, March 15, 2018 at 8:30 a.m. ET

NEWTON, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year end 2017 financial results on Thursday, March 15, 2018. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, March 15, 2018 to discuss the financial results and recent business developments.

To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least 10 minutes prior to the start time and refer to conference ID 1181109. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, [investors.karyopharm.com/events.cfm](https://investors.karyopharm.com/events.cfm). An archived webcast will be available on the Company's website approximately two hours after the event.

### About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 2,200 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade® (bortezomib) and low-dose dexamethasone (BOSTON) and in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in diffuse large B-cell lymphoma (SADAL) and liposarcoma (SEAL), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform the Company's clinical development priorities for selinexor. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit [www.karyopharm.com](http://www.karyopharm.com).

Velcade® is a registered trademark of Takeda Pharmaceutical Company Limited

### Contacts:

#### Investors:

Kimberly Minarovich  
(646) 368-8014  
[kimberly@argotpartners.com](mailto:kimberly@argotpartners.com)

Mary Jenkins  
(617) 340-6073  
[mary@argotpartners.com](mailto:mary@argotpartners.com)

Source: Karyopharm Therapeutics Inc.



<https://investors.karyopharm.com/2018-03-08-Karyopharm-to-Report-Fourth-Quarter-and-Year-End-2017-Financial-Results-on-March-15-2018>